🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. DTX401

    Ultragenyx UK Limited

    Glycogen Storage Disease Type IA

    phase 3 gene therapy completed

    1 trial

  2. Darbepoetin alfa

    Amgen

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  3. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  4. Dasiglucagon 4 mg/ml

    Zealand Pharma A/S

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial

  5. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  6. Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  7. Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  8. Dazodalibep

    Amgen

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  9. Deferiprone oral solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule completed

    1 trial

  10. Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  11. Denosumab

    Amgen

    Cancer

    phase 3 small molecule completed

    1 trial

  12. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  13. Dexamethasone

    Amgen

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  14. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials

  15. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials

  16. Dexlansoprazole MR QD

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial

  17. Dexmedetomidine Hcl 100 Mcg/mL Inj

    Hospital Authority, Hong Kong

    Congenital Heart Disease in Children

    phase 3 small molecule completed

    1 trial

  18. Dextrose / glucose 5% solution in water, Setrusumab

    Lacuna Pharma Pty Ltd

    Osteogenesis imperfecta (OI)

    phase 3 small molecule active

    1 trial

  19. Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category

    Aquestive Therapeutics

    Epilepsy

    phase 3 small molecule completed

    1 trial

  20. Diclofenac Sodium Topical Gel, 1%

    Amneal Pharma Europe Ltd

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  21. Dienogest

    Hospital Authority, Hong Kong

    Endometriosis

    phase 3 small molecule active

    1 trial

  22. Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets

    Mundipharma Pty Limited

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial

  23. Direct-Acting Oral Anticoagulants (used as per local standard practice)

    United Therapeutics Europe Ltd

    Traumatic Intracranial Haemorrhage

    phase 3 small molecule active

    1 trial

  24. Docetaxel+lobaplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources